Trial intelligence / Profile preview

Phase 1/2 selpercatinib study in pediatric patients with advanced RET-altered solid or primary CNS tumors

jRCT2080225127Phase 2Recruiting

Sponsor

Eli Lilly and Company / ICCC :Medpace Japan KK

Start

Mar 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules